Medically reviewed by Drugs.com. Last updated on Jun 18, 2018.
Applies to the following strengths: 6.25 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Mucositis
60 mcg/kg IV (as a bolus) once a day, administered for 3 consecutive days before and 3 consecutive days after myelotoxic therapy
-Prior to myelotoxic therapy: The third dose should be administered 24 to 48 hours prior to beginning the myelotoxic agent.
-Following myelotoxic therapy: The first dose should be administered on the day of hematopoietic stem cell infusion after the infusion is complete, AND at least 7 days after the most recent dose of this drug.
-Decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support
-Supportive care for preparative regiments predicted to result in greater than or equal to WHO Grade 3 mucositis in the majority of patients
Renal Dose Adjustments
No adjustment recommended.
Liver Dose Adjustments
Data not available
Safety and efficacy have not been established in patients younger than 1 year.
Consult WARNINGS section for additional precautions.
Data not available
-This drug should be given as a IV bolus injection; the solution should not be filtered.
-If heparin is used, IV lines should be rinsed with saline prior to and after administration.
-Prior to administration, this drug should be allowed to reach room temperature for up to 1 hour (protected from light); however, this drug will need to be discarded in excursions exceeding 1 hour.
-Unopened vials: Store refrigerated (2 to 8C), and protect from light. Do not freeze.
-Reconstituted solution: The solution may be stored refrigerated (2 to 8C) and protected from light in its carton for up to 24 hours; the solution should be discarded after 24 hours if it is not used.
-Reconstituted solutions left at room temperature for longer than 1 hour should be discarded.
Reconstitution/preparation techniques: The manufacturer product information should be consulted.
-Compatible: Sterile water for injection
-Other medications should not be added to solutions containing this drug.
-Safety and efficacy have not been established in patients with non-hematologic malignancies.
-This drug was not effective in decreasing severe mucositis in patients with hematologic malignancies who were receiving myelotoxic therapy with allogenic hematopoietic stem cell support.
-Once reconstituted, it is recommended that this drug is used immediately.
-Limitation of use: Treatment is not recommended for use with melphalan 200 mg/m2 as a conditioning regimen.
-HEMATOLOGIC: Platelet counts
-Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about palifermin
- Side Effects
- During Pregnancy
- Drug Interactions
- En Español
- Drug class: miscellaneous uncategorized agents
Other brands: Kepivance